Evotec and Shionogi enter Fragment-based Drug Discovery Alliance
Hamburg- German Evotec AG has entered into a drug discovery collaboration with Shionogi & Co Ltd. (Tokyo), to identify various small molecule modulators of various protein-protein interaction targets selected by Shionogi. Under the terms of the agreement, Evotec will apply its fragment-based drug discovery platform, EVOlution which utilises fragments of more complex molecules to generate efficient starting points for drug discovery. The platform combines biochemical and biophysical techniques such as nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography. The companies did not disclose any financial details of the deal.